CFDE Data Portal | Search RPP38-DT

	Label	Description
	RPP38-DT Gene (Entity type)	ENSG00000176236 - RPP38 divergent transcript
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE153871 cytarabine U2OS 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE249544 GSE249637 temozolomide 9 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE145650 COX2 inhibition 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS

RPP38-DT

ENSG00000176236 - RPP38 divergent transcript

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 0 v 6 human up

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE153871 cytarabine U2OS 5 v 2 human dn

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

GSE249544 GSE249637 temozolomide 9 v 5 human dn

A Gene Set from LINCS

GSE145650 COX2 inhibition 1 v 2 human up

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 5 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.